Advice

in the absence of a submission from the holder of the marketing authorisation:

adalimumab (Humira®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

NICE (National Institute for Health and Clinical Excellence) is currently undertaking a multiple technology appraisal (MTA) that includes the use of adalimumab in this indication.  However, due to the significant time interval between product availability and the expected date of NICE guidance, not recommended advice has been issued.

Download detailed advice111KB (PDF)

Download

Medicine details

Medicine name:
adalimumab (Humira)
SMC ID:
1209/16
Indication:
Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
Pharmaceutical company
AbbVie Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Non submission
Status
Superseded
Date advice published:
07 November 2016